Our mission is to outsmart cancer

By uniquely bringing Patient Selection into the
Target Identification stage.

Using the best model human

By using real patients data, we integrate target identification with cohort selection into a single coherent strategy.

Using best data patient tumor whole genome data

We use 100% of Genome Data, both Exome & Dark Genome alterations.
With a wealth of patient-derived tumor data, we can identify
novel drug targets “invisible” in cell line-based assays.

Targeting tumor vulnerabilities with  Synthetic lethality

Current targeted medicines focus on inhibiting oncogenes that drive tumor growth. However, oncogenes applicable to larger cohorts have already been explored.

Our primary therapeutic strategy is Synthetic Lethality, providing an opportunity to target tumors with inactivated suppressor genes as well as undruggable oncogenes.

Our mission is to outsmart cancer

Using the best model human

Using best data patient tumor whole genome data

Targeting tumor vulnerabilities with Synthetic lethality

Targeting tumor vulnerabilities with  Synthetic lethality